CNP 104
Alternative Names: CNP-104Latest Information Update: 13 Jan 2025
Price :
$50 *
At a glance
- Originator Cour Pharmaceutical Development
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Primary biliary cirrhosis
Most Recent Events
- 08 Jan 2025 CNP 104 receives Orphan Drug status for Primary biliary cirrhosis in USA
- 30 Sep 2024 Efficacy and adverse events data from a phase IIa trial in Primary biliary cirrhosis released by COUR Pharmaceuticals
- 27 Sep 2024 Ironwood Pharmaceuticals and COUR terminates the collaboration and license option agreement for CNP 104